Galanin-like peptide promotes feeding behaviour via activation of orexinergic neurones in the rat lateral hypothalamus.
Galanin-like peptide (GALP) is produced in neurones in the hypothalamic arcuate nucleus and is implicated in the neural control of feeding behaviour. Previously, we have reported that GALP immunoreactive fibres were in direct contact with orexin/hypocretin immunoreactive neurones in the rat lateral hypothalamus using double-immunofluorescence. Centrally administered GALP is known to stimulate feeding behaviour. However, the target neurones of this action have not been clarified. The present study aimed to determine features of the GALP-mediated neuronal feeding pathway in rat. Accordingly, at the ultrastructural level, GALP-immunoreactive axon terminals were found to make synapses on orexin/hypocretin immunoreactive cell bodies and dendritic processes in the lateral hypothalamus. c-Fos immunoreactivity was expressed in orexin/hypocretin-immunoreactive neurones but not in melanin concentrating hormone-immunoreactive neurones in the lateral hypothalamus at 90 min after the application of GALP by i.c.v. infusion. Furthermore, to determine whether GALP regulates feeding behaviour via orexin/hypocretin neurones, the feeding behaviour of rats was studied following GALP i.c.v. injection with or without anti-orexin A and B immunoglobulin (IgG) pretreatment. The anti-orexin IgGs markedly inhibited GALP-induced hyperphagia. These results suggest that orexin/hypocretin-containing neurones in the lateral hypothalamus are targeted by GALP, and that GALP-induced hyperphagia is mediated via orexin/hypocretin neurones in the rat hypothalamus.
Kageyama
H
H
Department of Anatomy, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
Kita
T
T
Toshinai
K
K
Guan
J-L
JL
Date
Y
Y
Takenoya
F
F
Kato
S
S
Matsumoto
H
H
Ohtaki
T
T
Nakazato
M
M
Shioda
S
S
D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000378:metabolism / Q000648:ultrastructure; D005247:Feeding Behavior / Q000502:physiology*; D044089:Galanin-Like Peptide / Q000008:administration & dosage / Q000502:physiology*; D007026:Hypothalamic Area, Lateral / Q000378:metabolism* / Q000648:ultrastructure; D007028:Hypothalamic Hormones / Q000378:metabolism; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008297:Male; D008543:Melanins / Q000378:metabolism; D009434:Neural Pathways / Q000378:metabolism; D009474:Neurons / Q000378:metabolism* / Q000648:ultrastructure; D009479:Neuropeptides / Q000378:metabolism*; D000068797:Orexins; D010907:Pituitary Hormones / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018709:Statistics, Nonparametric; D013569:Synapses / Q000378:metabolism / Q000648:ultrastructure; D014018:Tissue Distribution
D044089:Galanin-Like Peptide; D007028:Hypothalamic Hormones; D047908:Intracellular Signaling Peptides and Proteins; D008543:Melanins; D009479:Neuropeptides; D000068797:Orexins; D010907:Pituitary Hormones; C019463:melanin-concentrating hormone